

This product is not intended for diagnostic or medical purposes.

Gd-IgA1

ELISA


#27600 Gd-IgA1 Assay Kit – IBL

- Sample
Serum, EDTA plasma, Urine
- Measurement range
1.56 ~ 100 ng/mL
- Sensitivity
0.488 ng/mL
- Total Time
about 2.5 hour



- ① **Paraffin-embedded sections** (3µm thickness)
- ② Deparaffinization
- ③ Antigen retrieval treatment (0.05% bacterial protease subtilisin A)
**This process is extremely important. If the dose of bacterial protease subtilisin A is not enough, KM55 mAb staining will not be succeeded.*
- ④ Rinse
- ⑤ Protein Blocking
- ⑥ 1st Ab: Anti-Human Gd-IgA1(KM55) Rat IgG
- ⑦ Washes
- ⑧ 2nd Ab: Alexa Fluor 555(or Other colors)-conjugated goat anti-rat IgG antibody
- ⑨ Washes
- ⑩ Seal with Fluoromount

IBL's Gd-IgA1 ELISA kit has been widely used in IgAN related clinical researches and many used scientific papers were published worldwide since the kit was released. The assay was designed using a highly specific monoclonal antibody (KM55) for the purpose of stable measurement of Gd-IgA1.



KM55

#10777 Anti-Human Gd-IgA1(KM55) Rat IgG MoAb


- Application : IHC
- Species : Human
- Package size : 10µg, 100µg

Antibody (KM55) for IHC against IgAN is Available!

KM55 MoAb




Anti-IgA



This product is not intended for diagnostic or medical purposes.

PMID	Cite
35570983	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. M Mathur et al. <i>Kidney Int Rep.</i> 2022 Feb 8;7(5):993-1003..
37114051	Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy. Y Nihei et al. <i>Front Immunol.</i> 2023 Apr 11;14:1165394.
36862654	cnm-positive <i>Streptococcus mutans</i> is associated with galactose-deficient IgA in patients with IgA nephropathy. Misaki T, et al. <i>PLoS One.</i> 2023 Mar 2;18(3):e0282367.
35683557	Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy. Y Fukao et al. <i>J Clin Med.</i> 2022 Jun 2;11(11):3173. .
34570260	IgA glycosylation and immune complex formation in IgAN. Suzuki, H et al. <i>Semin Immunopathol.</i> 2021 Oct;43(5):669-678.
33818625	IgA vasculitis with nephritis: update of pathogenesis with clinical implications. M.C. Hastings et al. <i>Pediatr Nephrol.</i> 2022 Apr;37(4):719-733.
37286948	Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression. S Eliasdottir et al. <i>BMC Nephrol.</i> 2023 Jun 7;24(1):160.
35887995	Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy. Y-T Juan et al. <i>J Clin Med.</i> 2022 Jul 21;11(14):4231.
34764788	Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study. M Mizerska-Wasiak et al. <i>Cent Eur J Immunol.</i> 2021;46(2):199-209.
33741175	Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. L Martín-Penagos et al. <i>Nefrologia (Engl Ed).</i> 2021 May-Jun;41(3):311-320.
34177889	Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Y-L Chiu et al. <i>Front Immunol.</i> 2021 Jun 10;12:638309.



Distributed by:



Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246

Email: info@IBL-America.com

Web: www.IBL-America.com